CJC-1295 + Ipamorelin: The Classic Stack Explained
The most popular growth-hormone peptide combination there is — and for a good reason rooted in biology. Here's why pairing these two produces more than either can alone.
This guide explains the CJC-1295 + Ipamorelin combination based on published pharmacology. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
If you spend any time researching growth-hormone peptides, one combination comes up more than any other: CJC-1295 paired with Ipamorelin. It's the classic stack — the default protocol in the peptide community — and its popularity isn't hype or marketing. It's built on a genuine biological logic: these two peptides work through different pathways to the same goal, so together they do something neither can do alone.
This guide explains exactly why the pairing works, the crucial "DAC vs No-DAC" distinction that trips people up, how it's dosed, and an honest look at the evidence.
Why This Is THE Stack
To understand the stack, you need one key idea from our pillar guide on how growth hormone peptides work: there are two different "doors" your pituitary uses to release growth hormone. GHRH analogs open one door; ghrelin-mimetic peptides (GHRPs) open the other. CJC-1295 and Ipamorelin are one peptide from each door — and opening both doors at once is the whole point.
The Two Peptides in Brief
CJC-1295
A GHRH analog that binds the GHRH receptor on the pituitary and tells it to make and build up growth hormone — it amplifies the pituitary's readiness to release GH.
Ipamorelin
A selective ghrelin-receptor (GHS-R) agonist that tells the pituitary to release the GH it has — and simultaneously suppresses somatostatin, the body's main "GH brake." Known as the "cleanest" GHRP.
Ipamorelin's selectivity is worth a note: unlike older GHRPs, it triggers GH release with minimal effect on cortisol (stress) or prolactin, and with little of the hunger some of its cousins cause — which is why it's the preferred Door 2 partner.
Why They're Combined: The Synergy
Here's the elegant part. CJC-1295 and Ipamorelin do three complementary jobs on the same pituitary cell:
1. Make it (CJC-1295)
CJC-1295 stimulates the pituitary to produce and prime growth hormone, increasing how much is ready to go.
2. Release it (Ipamorelin)
Ipamorelin triggers the actual release pulse — telling the pituitary to let that stored growth hormone out.
3. Remove the brake (Ipamorelin)
At the same time, Ipamorelin suppresses somatostatin — the hormone that normally puts the brakes on GH release.
Because these act on two different receptor pathways at once, the result isn't just additive — it's synergistic. Activating both doors together makes the pituitary release a substantially larger pulse of growth hormone than either peptide could trigger alone (research commonly describes the combined pulse as several times greater). You're building it up, releasing it, and lifting the brake — all in one coordinated signal.
The Synergy at a Glance
CJC-1295 builds and primes the growth hormone; Ipamorelin releases it and removes the somatostatin brake. Two pathways firing together produce a pulse larger than the sum of its parts.
The DAC vs No-DAC Question
This is the detail that confuses most people — and it genuinely matters. CJC-1295 comes in two forms, and they behave very differently:
| CJC-1295 without DAC (Mod GRF 1-29) | CJC-1295 with DAC | |
|---|---|---|
| Half-life | Short (~30 min–2 hours) | Long (~6–8 days) |
| GH pattern | Distinct natural pulses | Sustained elevation |
| Dosing | Multiple times daily (with Ipamorelin) | Weekly or twice-weekly |
| Fit with Ipamorelin | Excellent — half-lives match | Less natural — different rhythm |
Why the classic stack traditionally uses No-DAC
The DAC (Drug Affinity Complex) modification binds the peptide to albumin in your blood, stretching its half-life to about a week. That's convenient (fewer injections), but it produces a sustained GH elevation rather than distinct pulses. The classic pulsatile stack traditionally pairs CJC-1295 without DAC with Ipamorelin, because its short half-life matches Ipamorelin's roughly two-hour window — so the two fire together and preserve your body's natural pulsing rhythm. The DAC version can still be used for its convenience and sustained profile, but it's a different protocol with a different rhythm (and some note it can blunt natural pulsatility over time). Which you choose depends on whether you prioritize natural pulsatility or dosing convenience — a good thing to discuss with a knowledgeable provider. See our CJC-1295 page for the product details.
Dosing the Stack
The following reflects commonly reported protocols for the classic (No-DAC) pulsatile stack. It is a general informational reference, not a medical recommendation.
| Aspect | Typical Approach |
|---|---|
| Ratio | 1:1 — matched doses of each peptide |
| Common dose | ~100 mcg CJC-1295 (No-DAC) + ~100 mcg Ipamorelin per injection |
| Saturation point | ~100 mcg is roughly the "saturation dose" — more doesn't give proportionally more GH |
| Frequency | 1–3 times daily (e.g., morning, post-workout, bedtime) |
| Same syringe? | Yes — both are commonly reconstituted together and given in one injection |
The "saturation dose" concept
A useful thing to know: around 100 mcg of CJC-1295 (No-DAC) is considered a saturation dose — the point where you're getting most of the available GH-release benefit from that pulse. Going much higher doesn't produce proportionally more growth hormone; it mostly wastes peptide. This is why the standard protocol centers on ~100 mcg per dose rather than ever-larger amounts, and why dosing more frequently (more pulses) is generally favored over dosing bigger.
Both peptides come as lyophilized powder, reconstituted with bacteriostatic water. See our reconstitution guide and dosing basics for the practical steps.
Timing & Practical Tips
- Empty stomach. Elevated blood sugar and insulin (from food, especially carbs) blunt GH release — so dose away from meals, ideally 20+ minutes before eating.
- Bedtime dosing is popular. Your biggest natural GH pulse happens during deep sleep, so a bedtime dose reinforces it. Many people use a bedtime dose as their anchor.
- Post-workout is another window. Exercise naturally triggers GH, so some time a dose around training.
- Consistency beats intensity. Effects build gradually over weeks and months — steady daily dosing matters far more than large doses.
Benefits & Timeline
The stack's benefits are those of improved growth-hormone signaling, arriving in a fairly consistent order:
Sleep (often first)
Deeper, more restorative sleep is frequently the earliest noticeable effect — sometimes within the first weeks.
Recovery & Energy
Improved recovery from exercise and better daytime energy tend to follow.
Body Composition
Gradual fat reduction and improved muscle tone typically become apparent over 2–3 months of consistent use.
Skin & Wellbeing
Support for skin quality and a general sense of vitality, as part of the broader anti-aging picture.
Expect gradual body-composition shifts over months, not dramatic weight loss — this is a GH-support stack, not a weight-loss drug like the GLP-1 peptides.
Safety & Honest Evidence
The stack is generally reported to be well tolerated, with side effects typical of GH peptides — but a few honest points matter.
Common side effects
- Injection-site reactions — redness, minor swelling, occasional bruising
- Mild water retention — sometimes in the first few weeks
- Occasional tingling or numbness — more likely at higher CJC-1295 doses
- Head-rush or flushing — briefly after injecting, uncommonly
The honest evidence picture
Here's the candid truth: no published human randomized trial has tested the CJC-1295 + Ipamorelin combination at the doses commonly used. The case for the stack rests on each compound's individual human pharmacokinetic data plus well-established cellular and animal evidence that the two pathways are synergistic on the same pituitary cell. So the mechanism is well-grounded and each peptide is individually studied — but the specific stack itself isn't proven in human trials. Both are research compounds, not FDA-approved, and their regulatory status has been evolving in 2026. Because they raise GH and IGF-1, both warrant caution in anyone with a history of cancer, can affect blood sugar, and are banned in competitive sport by WADA. Anyone with a cancer history, diabetes, or a pituitary condition should consult a doctor first. See our when to consult a doctor guide.
Common Questions
Why are CJC-1295 and Ipamorelin used together?
Because they work through two different pathways to boost growth hormone, so together they're greater than the sum of their parts. CJC-1295 (a GHRH analog) tells the pituitary to make GH; Ipamorelin (a GHRP) tells it to release GH and lifts the somatostatin "brake." Firing both pathways at once produces a substantially larger GH pulse than either alone — often described as several times greater. That two-door synergy is the entire rationale for the classic stack.
Should I use CJC-1295 with DAC or without DAC in the stack?
The classic pulsatile stack traditionally uses CJC-1295 without DAC (Mod GRF 1-29), because its short half-life (~30 min–2 hours) matches Ipamorelin's, so they fire together and preserve natural GH pulses. The DAC version has a ~6–8 day half-life, giving sustained elevation and weekly dosing — convenient, but a different rhythm that fits Ipamorelin's short pulse less naturally, and some note it can blunt natural pulsatility. The choice comes down to natural pulsatility vs dosing convenience.
How much CJC-1295 and Ipamorelin should be used?
The standard approach for the No-DAC stack is a 1:1 ratio — commonly around 100 mcg of each per injection, 1–3 times daily. About 100 mcg of CJC-1295 is considered the "saturation dose," meaning going higher doesn't give proportionally more GH release. That's why the protocol favors dosing more frequently (more pulses) rather than larger amounts. This is general information, not a prescription — actual dosing should be worked out with a knowledgeable healthcare professional.
Can I mix them in the same syringe?
Yes — the most common community and clinic approach is to reconstitute both peptides together (or draw both into one syringe) so a single injection delivers both. This reduces the number of injections and simplifies dosing. For example, a matched 100 mcg + 100 mcg dose can be given in one shot. Follow proper reconstitution and handling practices, and verify your specific doses before drawing.
When should I take the stack?
On an empty stomach (20+ minutes before eating), because food — especially carbs — raises insulin and blunts GH release. Bedtime is the most popular timing, since it reinforces your largest natural nighttime GH pulse; post-workout is another common window. Many people anchor with a bedtime dose and add others if dosing more than once daily. Consistency matters far more than perfect timing.
How long until I see results?
Better sleep is often noticed first, sometimes within the first few weeks. Recovery and energy tend to follow. Body-composition changes — gradual fat reduction and improved muscle tone — typically become apparent over about 2–3 months of consistent use. This is a gradual GH-support stack, not a dramatic or rapid weight-loss protocol, so patience and consistency are what deliver results.
Is the stack proven and safe?
Each peptide is individually studied and the two-pathway synergy is well-established in cellular and animal research — but no published human randomized trial has tested this specific combination at common doses, so the stack rests on mechanism plus individual data rather than direct trial proof. Both are research compounds, not FDA-approved. They're generally reported as well tolerated (mainly injection-site effects, mild water retention), but they raise IGF-1 (a cancer caution), can affect blood sugar, and are WADA-banned. Professional guidance is wise.
Is this stack legal in Costa Rica?
These peptides are sold as research compounds in Costa Rica, the same framework used in most countries with active peptide markets, for laboratory and research purposes. Buying locally avoids the heat exposure that international shipping puts delicate, heat-sensitive GH peptides through. See our FAQ page for more.
Questions about the CJC-1295 + Ipamorelin stack?
Whether you want to understand the synergy, the DAC vs No-DAC choice, or how it fits your goals, we're happy to help — honestly, including the limits of the evidence. We answer every message personally, with no pressure and no upsell.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. CJC-1295 and Ipamorelin are not approved by the FDA or Costa Rica's Ministerio de Salud as treatments for any condition; they are sold as research compounds intended for laboratory and scientific study, not as substitutes for prescribed, medically supervised treatment. No published human randomized trial has tested this specific combination at commonly used doses; the rationale rests on individual pharmacokinetic data and preclinical synergy evidence. These compounds raise growth hormone and IGF-1, can affect blood sugar, warrant caution in anyone with a history of cancer, and are prohibited in competitive sport by WADA. Always consult a qualified healthcare professional before beginning any peptide protocol. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006): CJC-1295 sustained GH and IGF-1 elevation in healthy adults.
- Endocrinology (Bowers et al.): GHRH + GHRP synergy — combined stimulation of pituitary somatotrophs.
- Sexual Medicine Reviews (Sigalos & Pastuszak, 2018): The safety and efficacy of growth-hormone secretagogues.
- NCBI/PMC: Ipamorelin — selective GHS-R1a agonism with minimal cortisol/prolactin effect and somatostatin suppression.
- NCBI/PMC: CJC-1295 DAC vs Mod GRF (1-29) — albumin binding, half-life, and pulsatile vs sustained GH release.
- FDA Bulk Drug Substances (503A) & 2026 regulatory updates: Compounding status of CJC-1295 and ipamorelin.
- Nature Reviews Drug Discovery: "Therapeutic peptides: current applications and future directions."
